Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly
Julian
J
Schad
Moritz
M
Laufs
Stephanie
S
Melo
Junia V
JV
Zeller
W Jens
WJ
Fruehauf
Stefan
S
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016227:Benzoquinones; D015153:Blotting, Western; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D000068877:Imatinib Mesylate; D020014:K562 Cells; D047029:Lactams, Macrocyclic; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017828:Rifabutin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D047029:Lactams, Macrocyclic; D010879:Piperazines; D011743:Pyrimidines; D017828:Rifabutin; C112765:tanespimycin; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl